Literature DB >> 9366416

Appropriate developmental expression of human CD8 beta in transgenic mice.

L J Kieffer1, L Yan, J H Hanke, P B Kavathas.   

Abstract

The human CD8 glycoprotein is expressed either as an alpha beta heterodimer or as an alpha alpha homodimer on thymocytes, mature T cells, and subpopulations of intestinal intraepithelial lymphocytes (IELs). The homodimeric form of CD8 is exclusively expressed on TCR gamma delta IELs and on subsets of NK cells and TCR alpha beta IELs. To understand the molecular mechanisms by which these genes are regulated, we created transgenic mice with a 95-kb human genomic DNA fragment containing the entire CD8 beta gene as well as a cluster of tissue-specific DNase I-hypersensitive sites 7 to 10 kb upstream of the gene. These sites were present in CD8 alpha beta+- but not CD8 alpha beta- T cell lines nor in a B cell line. We found that transgenic mice had correct developmental expression of human CD8 beta on thymocytes and mature CD8+ cells and no expression on mature CD4+ T cells or B cells. Interestingly, the percentage of mouse CD8 alpha+ cells that were human CD8 beta+ varied, depending on the founder line, from 4 to 88%, whereas the percentage among siblings was similar, indicative of a variegated phenotype resulting from site of integration effects. Expression was also observed on intestinal IELs, but only on those expressing the TCR alpha beta receptor and not the TCR gamma delta cells, which exclusively express CD8 alpha alpha. Of the TCR alpha beta+ cells, the transgene was expressed in both the CD8 alpha alpha and alpha beta subpopulations. These results indicate that this 95-kb fragment affords developmentally correct expression of the human CD8 beta gene on thymus-derived T cells in transgenic animals. Therefore, CD8 lineage-specific regulatory sequences must be located within the fragment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9366416

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Active chromatin domains are defined by acetylation islands revealed by genome-wide mapping.

Authors:  Tae-Young Roh; Suresh Cuddapah; Keji Zhao
Journal:  Genes Dev       Date:  2005-02-10       Impact factor: 11.361

2.  Differential modulation of CD8beta by rat gammadelta and alphabeta T cells after activation.

Authors:  F Straube; T Herrmann
Journal:  Immunology       Date:  2001-11       Impact factor: 7.397

3.  cAMP-responsive element modulator α (CREMα) trans-represses the transmembrane glycoprotein CD8 and contributes to the generation of CD3+CD4-CD8- T cells in health and disease.

Authors:  Christian M Hedrich; Thomas Rauen; Jose C Crispin; Tomohiro Koga; Christina Ioannidis; Melissa Zajdel; Vasileios C Kyttaris; George C Tsokos
Journal:  J Biol Chem       Date:  2013-09-18       Impact factor: 5.157

4.  cAMP responsive element modulator (CREM) α mediates chromatin remodeling of CD8 during the generation of CD3+ CD4- CD8- T cells.

Authors:  Christian M Hedrich; José C Crispín; Thomas Rauen; Christina Ioannidis; Tomohiro Koga; Noe Rodriguez Rodriguez; Sokratis A Apostolidis; Vasileios C Kyttaris; George C Tsokos
Journal:  J Biol Chem       Date:  2013-12-02       Impact factor: 5.157

Review 5.  The epigenetic landscape of lineage choice: lessons from the heritability of CD4 and CD8 expression.

Authors:  Manolis Gialitakis; Maclean Sellars; Dan R Littman
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

Review 6.  Transcriptional control of CD4 and CD8 coreceptor expression during T cell development.

Authors:  Wilfried Ellmeier; Lena Haust; Roland Tschismarov
Journal:  Cell Mol Life Sci       Date:  2013-06-21       Impact factor: 9.261

7.  Transcriptional fates of human-specific segmental duplications in brain.

Authors:  Max L Dougherty; Jason G Underwood; Bradley J Nelson; Elizabeth Tseng; Katherine M Munson; Osnat Penn; Tomasz J Nowakowski; Alex A Pollen; Evan E Eichler
Journal:  Genome Res       Date:  2018-09-18       Impact factor: 9.043

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.